An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Public ClinicalTrials.gov record NCT04136808. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (EV-901)
Study identification
- NCT ID
- NCT04136808
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- enfortumab vedotin (EV) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 12, 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology Oncology | Los Angeles | California | 90095 | — |
| John Wayne Cancer Institute | Santa Monica | California | 90404 | — |
| St. Joseph Heritage Medical Group | Santa Rosa | California | 95403 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32204 | — |
| Northwestern University Medical Center | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Community Hospital Anderson | Anderson | Indiana | 46011 | — |
| New England Cancer Specialists | Topsham | Maine | 04086 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04136808, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04136808 live on ClinicalTrials.gov.